Novavax Inc. closed 59.74% below its 52-week high of $17.81, which the company achieved on July 26th.

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Novavax Inc. closed 60.92% short of its 52-week high of $17.81, which the company reached on July 26th.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Philip Morris International Inc. (PM) ...

View the latest Novavax Inc. (NVAX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.